Standard BioTools Inc. Depreciation
Standard BioTools Inc. (LAB) reported Depreciation of $2.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- Standard BioTools Inc. depreciation for the quarter ending 2026-06-30 was $1.30M, a 35.00% decline year-over-year.
- Standard BioTools Inc. depreciation for the quarter ending 2026-03-31 was $1.40M, a 33.33% decline year-over-year.
- Standard BioTools Inc. depreciation for the quarter ending 2025-12-31 was $1.30M, a 62.50% increase year-over-year.
- Standard BioTools Inc. depreciation for the quarter ending 2025-09-30 was $1.50M, a 50.00% increase year-over-year.
- Standard BioTools Inc. depreciation for fiscal 2025 was $6.90M, a 81.58% increase from fiscal 2024.
- Standard BioTools Inc. depreciation for fiscal 2024 was $3.80M, a 11.76% increase from fiscal 2023.
- Standard BioTools Inc. depreciation for fiscal 2023 was $3.40M, a 21.43% increase from fiscal 2022.
- Standard BioTools Inc. depreciation for fiscal 2022 was $2.80M, a 0.00% change from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.70M 10-Q · filed 2026-08-05 | $4.00M derived: sum of 3 quarters · filed 2026-08-05 | $5.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-06 | $2.70M derived: sum of 2 quarters · filed 2026-05-06 | $4.20M derived: sum of 3 quarters · filed 2026-05-06 | $6.20M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.80M derived: sum of 2 quarters · filed 2026-03-16 | $4.80M derived: sum of 3 quarters · filed 2026-03-16 | $6.90M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $1.50M 10-Q · filed 2025-11-04 | $3.50M derived: sum of 2 quarters · filed 2025-11-04 | $5.60M 10-Q · filed 2025-11-04 | $6.40M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2025-06-30 | $2.00M 10-Q · filed 2025-08-15 | $4.10M 10-Q · filed 2026-08-05 | $4.90M derived: sum of 3 quarters · filed 2026-05-06 | $5.90M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2025-03-31 | $2.10M 10-Q · filed 2026-05-06 | $3.30M 10-Q · filed 2025-05-06 | $2.90M derived: sum of 2 quarters · filed 2026-05-06 | $3.90M derived: sum of 3 quarters · filed 2026-05-06 | $4.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.80M derived: sum of 2 quarters · filed 2026-03-16 | $2.80M derived: sum of 3 quarters · filed 2026-03-16 | $3.80M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-04 | $2.00M derived: sum of 2 quarters · filed 2025-11-04 | $3.00M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $1.00M 10-Q · filed 2025-08-15 | $2.00M 10-Q · filed 2025-08-15 | |||
| 2024-03-31 | $3.00M 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | $3.40M 10-K · filed 2026-03-16 | ||||
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $2.80M 10-K · filed 2024-03-01 | ||||
| 2021-12-31 | $2.80M 10-K · filed 2023-03-14 | ||||
| 2020-12-31 | $3.10M 10-K · filed 2022-03-08 | ||||
| 2019-12-31 | $3.60M 10-K · filed 2022-03-08 | ||||
| 2018-12-31 | $4.20M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $5.90M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $5.10M 10-K · filed 2019-03-18 | ||||
| 2015-12-31 | $3.60M 10-K · filed 2018-03-08 | ||||
| 2014-12-31 | $3.00M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |